^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    FG-3246

    i
    Other names: FG-3246, FOR46, FOR 46, FG3246, FG 3246, FOR-46
    Associations

    News

    Trials
    Company:
    FibroGen, Fortis Therap
    Drug class:
    Microtubule inhibitor, CD46-targeted antibody-drug conjugate
    Related drugs:
    Associations

    News

    Trials
    11ms
    A Phase 1 Study of FOR46 in Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC) (clinicaltrials.gov)
    P1, N=56, Completed, Fortis Therapeutics, Inc. | Active, not recruiting --> Completed
    Trial completion
    |
    CD46 (CD46 Molecule)
    |
    FG-3246
    over4years
    A Phase 1 Study of FOR46 in Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC) (clinicaltrials.gov)
    Trial completion date: Jun 2020 --> Dec 2021 | Trial primary completion date: Apr 2020 --> Apr 2021
    Clinical • Trial completion date • Trial primary completion date
    |
    CYP17A1 (Cytochrome P450 Family 17 Subfamily A Member 1)
    |
    FG-3246